LumiraDx Q4 revenues drop 65% on lower COVID-19 testing : vi

The firm recorded an accounting impairment in Q4 for excess manufacturing and inventory related to the scale-up during peak COVID-19 testing demand and the decision to pause commercialization of its Amira COVID-19 test.

Related Keywords

United States , London , City Of , United Kingdom , Ron Zwanziger , National Institutes Of Health , Drug Administration , Test Assessment Program , Fast Labs , Independent Test Assessment Program , National Institutes , Amira System ,